Kei Ito

Dr. Kei Ito

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2019 in Pathobiology
Verified
Journal Article
Closed access
PDF file
KIKei Ito
Kei Ito
HOHideaki Ogata
Hideaki Ogata
NHNaoko Honma
Naoko Honma
KSKazutoshi Shibuya
Kazutoshi Shibuya
TMTetuo Mikami
Tetuo Mikami
Introduction: Triple-negative breast cancer (TNBC), which lacks expression of estrogen receptor (ER), progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2), currently has no effective hormonal or molecular target therapy. Objective and Methods: To elucidate the role of the mammalian target of rapamycin (mTOR) signaling pathway in TNBC, the expression of molecules involved in mTOR signaling including mTOR, phosphorylated (p)-mTOR, p-4EBP1, GLUT1, GLUT3, HIF-1α, and Ki67 was investigated by immunohistochemistry in 35 TNBC and 81 non-TNBC cases. Results: Expression of p-mTOR, the activated form of mTOR, but not unphosphorylated mTOR, was significantly higher in non-TNBC cases than in TNBC cases. Expression of p-4EBP1, GLUT1, and GLUT3 was higher in TNBC cases than in non-TNBC cases. When the localization of p-mTOR was classified as nuclear, perinuclear, or cytoplasmic, nuclear localization of p-mTOR was observed more frequently in TNBC than in non-TNBC cases and was correlated with the expression of GLUT1 and GLUT3, which was related to proliferation activity examined with Ki67. Conclusions: mTOR signaling regulates cell proliferation in some cases of TNBC and may be a potential target of molecular therapy for TNBC.

18 October 2023 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
KFKazuko Fujita
Kazuko Fujita
TKTaku Kuwabara
Taku Kuwabara
Bing WangBing Wang
Bing Wang
KTKaoru Tanaka
Kaoru Tanaka
KIKei Ito
Kei Ito
TIToshiharu Ishii
Toshiharu Ishii
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies that can induce systemic inflammation. Ultraviolet-A and X-ray irradiation have been reported to have therapeutic effects in patients with SLE. We previously demonstrated that CD180-negative cells, these are radiosensitive, contribute to the development of SLE-like morbidity in NZBWF1 mice. In this study, the effects of irradiation on SLE-like morbidity manifestations in NZBWF1 mice and on CD180-negative cells were investigated. Whole-body irradiation, excluding the head, attenuated SLE-like morbidity in vivo, as indicated by the prevention of the renal lesion development, inhibition of anti-dsDNA antibody production, reduction of urinary protein levels, and prolongation of the lifespan. Irradiation also reduced the proportion of CD180-negative cells in the spleen. Although other immune cells or molecules may be triggered because of the whole-body irradiation treatment, previous research, and the current results suggest a strong relationship between the radiation-induced decrease in CD180-negative cells and the amelioration of SLE-like morbidities. Clinical trials assessing CD180-negative cells as a therapeutic target for SLE have been hampered by the lack of validated cell markers; nonetheless, the present findings suggest that radiotherapy may be a new therapeutic strategy for managing SLE symptoms.

24 April 2024 in Pathology International
Verified
Journal Article
Closed access
KIKei Ito
Kei Ito
NHNaoko Honma
Naoko Honma
HOHideaki Ogata
Hideaki Ogata
AYAkimitsu Yamada
Akimitsu Yamada
MMMika Miyashita
Mika Miyashita
MSMasataka Sawaki
Masataka Sawaki

1 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SMShuhei Mashimo
Shuhei Mashimo
TKTaku Kuwabara
Taku Kuwabara
KIKei Ito
Kei Ito
TMTetuo Mikami
Tetuo Mikami
AIAkira Ishiko
Akira Ishiko
MKMotonari Kondo
Motonari Kondo
Mitochondrial transcription factor A (TFAM) is a key regulator of mitochondrial DNA transcription and replication. T cell‐specific TFAM‐deficient mice are immunocompromised, often succumbing to viral infection, and their T cells are unresponsive to T‐cell antigen receptor (TCR) stimulation, suggesting that TFAM‐mediated mitochondrial activity regulates T‐cell activity, such as effector function and memory formation. In contrast to the attenuation of immune response, TFAM deficiency may also induce inflammatory responses, raising the possibility that TFAM deficiency results in inflammation‐mediated autoimmune responses. Thus, besides regulating T‐cell function, TFAM plays important roles in autoimmune responses. However, its role in autoimmune diseases remains uncertain. We aimed to investigate the role of TFAM in autoimmune diseases using T cell‐specific TFAM‐deficient mice. We detected anti‐double‐strand (ds) DNA antibody, and interferon alpha (IFNα) and IFNγ in the serum of TFAM fl/fl CD4Cre mice after 30 weeks of age. Mononuclear cell infiltration was observed in the kidneys. TFAM‐deficient T cells exhibited leakage of mitochondrial DNA into the cytoplasm. Cytoplasmic mitochondrial DNA was associated with activation of TANK‐binding kinase 1 (TBK1) and IFN regulatory factor 3 (IRF3)—the downstream molecules of the nucleic acid sensor cyclic guanosine monophosphate–adenosine monophosphate synthase/stimulator of IFN genes (cGAS/STING) machinery. mRNA expression of type I IFN genes was elevated in T cells from TFAM fl/fl CD4Cre mice. The suppressive function of Foxp3 + regulatory T (Treg) cells, which play a major role in establishment of peripheral tolerance, was reduced in the absence of TFAM. Our findings suggest that T cells in TFAM‐deficient conditions may contribute to immune instability and autoimmune responses by inducing type I IFN‐mediated inflammatory responses.

Verified
Journal Article
Open access
PDF file
KIKei Ito
Kei Ito
NHNaoko Honma
Naoko Honma
HOHideaki Ogata
Hideaki Ogata
AYAkimitsu Yamada
Akimitsu Yamada
MMMika Miyashita
Mika Miyashita
MSMasataka Sawaki
Masataka Sawaki
In triple-negative breast cancer (TNBC), the clinicopathological significance of the expression of a second estrogen receptor, ERβ, remains unclear. Further, although the clinicopathological significance of mutant p53 and androgen receptor (AR) has been investigated in TNBC, they have not been established as therapeutic targets. Experimental studies reported the importance of cross-talk between ERβ and p53 or AR in TNBC. In this study, we immunohistochemically examined ERβ expression in surgical specimens of TNBC obtained from postmenopausal patients who underwent surgery without neoadjuvant therapy and investigated the relationship between ERβ expression and various clinicopathological factors, including clinical outcome, while also considering p53 and AR. No significant difference in clinical outcome was noted according to the ERβ status alone (p = 0.2908). However, the ERβ status did affect the relationship between the clinical outcome and p53 or AR status; p53-positive or AR-positive group exhibited significantly more favorable clinical outcomes than p53-negative or AR-negative group, respectively, in the ERβ-positive group (p53, p = 0.0265; AR, p = 0.0285), but not in the ERβ-negative group (p53, p = 0.7228; AR, p = 0.7734). This may be the result of a functional interaction between ERβ and p53 or AR. The role of ERβ in TNBC will be elucidated in further complex studies considering multiple molecules.